← Ticker index
PODD
Ticker
PODD
Congressional Trades
29
by 2 members
Ticker disclosure brief
Congressional disclosure records for PODD
A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.
Latest receipt
Ro Khanna
BUY · 2026-06-16
Largest range
$250K – $500K
Tina Smith
Longest observed gap
39d
Ro Khanna
Highest 30d vs SPY
11.2%
Ro Khanna
Purchase rows
10
34%
Sale rows
12
41%
Disclosed midpoint
$1.8M
range estimate
Unique Traders
2
members
Disclosure timing method
Observed filing gaps are not notice-date findings
The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.
Party Breakdown
Democrats29 · 100%
Republicans0 · 0%
Lobbying filings
all →- 2026-07-12$60KINSULET CORPORATIONGeneral education on diabetes care. General education about Insulet.
- 2026-04-20$140KINSULET CORPORATIONIssues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to talks of future budget reconciliation package. Issues related to the reintroduction of the DIABETES Act (S.4037) in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade and the Sec. 232 Tariff investigation related to Medical Devices. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to National Coverage Determination revisions specifically in reference to durable infusion insulin pumps. Issues related to Prior Authorizations in Medicare Advantage plan
- 2026-04-20$60KINSULET CORPORATIONGeneral education on diabetes care. General education about Insulet.
- 2026-01-19$140KINSULET CORPORATIONIssues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to budget reconciliation package. Issues related to the reintroduction or possible reintroduction of the DIABETES Act in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to National Coverage Determination revisions specifically in reference to insulin pumps. Issues related to Prior Authorizations in Medicare Advantage plans. Issues related to support of Improving Seniors' Timely Access to Care Act. Is
- 2026-01-17$50KINSULET CORPORATIONGeneral education on diabetes care. General education about Insulet.
- 2025-10-17$110KINSULET CORPORATIONIssues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to budget reconciliation package. Issues related to the reintroduction or possible reintroduction of the DIABETES Act in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to Prior Authorizations in Medicare Advantage plans. Issues related to support of Improving Seniors' Timely Access to Care Act. Issues related to CMS notice of proposed rule, DMEPOS Home Health Rule.
- 2025-10-12$50KINSULET CORPORATIONGeneral education on diabetes care. General education about Insulet.
- 2025-07-30$40KINSULET CORPORATIONGeneral education on diabetes care. General education about Insulet.
- 2025-07-21$130KINSULET CORPORATIONIssues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to budget reconciliation package. Issues related to the reintroduction or possible reintroduction of the DIABETES Act in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to Prior Authorizations in Medicare Advantage plans. Issues related to support of Improving Seniors' Timely Access to Care Act.
- 2025-07-21$0INSULET CORPORATIONGeneral education on diabetes care. General education about Insulet.
Loading trade analytics…
All Disclosed Trades
Page 2 · 4 of 29 shown| Date | Member | Action | Amount | Observed Gap | Receipt |
|---|---|---|---|---|---|
| 2024-04-04 | DTina Smith | PARTIAL_SELL | $50K – $100K | 16d | receipt → |
| 2024-04-04 | DTina Smith | PARTIAL_SELL | $50K – $100K | 15d | receipt → |
| 2024-04-04 | DTina Smith | PARTIAL_SELL | $50K – $100K | 15d | receipt → |
| 2020-03-17 | DTina Smith | PARTIAL_SELL | $250K – $500K | 1259dApparent delay | receipt → |
“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.